MA37944A1 - Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson - Google Patents
Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinsonInfo
- Publication number
- MA37944A1 MA37944A1 MA37944A MA37944A MA37944A1 MA 37944 A1 MA37944 A1 MA 37944A1 MA 37944 A MA37944 A MA 37944A MA 37944 A MA37944 A MA 37944A MA 37944 A1 MA37944 A1 MA 37944A1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- halogen
- substituted
- disorders
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
La présente invention concerne des composés de formule (i) dans laquelle r1 est phényle, facultativement substitué par halogène, alkyle inférieur, cycloalkyle inférieur, alcoxy inférieur, cyano, alkyle inférieur substitué par halogène, alkyle inférieur substitué par hydroxy, alcoxy inférieur substitué par halogène ou alcoxy inférieur substitué par hydroxy ; ou est pyridine-2, 3 ou 4-yle, facultativement substitué par halogène, alkyle inférieur, cycloalkyle inférieur, cyano, alkyle inférieur substitué par halogène, alkyle inférieur substitué par hydroxy, alcoxy inférieur, alcoxy inférieur substitué par halogène ou alcoxy inférieur substitué par hydroxyle ; ou est pyrimidin-2, 4 ou 5-yle, facultativement substitué par halogène, alkyle inférieur, cycloalkyle inférieur, alkyle inférieur substitué par hydroxy ou alkyle inférieur substitué par halogène ; ou est pyrazin-2-yle, facultativement substitué par halogène, alkyle inférieur, cycloalkyle inférieur, alkyle inférieur substitué par halogène, alkyle inférieur substitué par hydroxy ou cyano ; ou est 2,2-difluorobenzo[d][1,3]dioxol-5-yle, ou est thiazolyle, facultativement substitué par alkyle inférieur substitué par halogène ; r2 est hydrogène ou alkyle inférieur ; r3 est hydrogène, amino ou alkyle inférieur ; z est une liaison, -ch2- ou -o- ; ou un sel d'addition d’acide pharmaceutiquement adapté. Il a maintenant été découvert que les composés de formule i ont une bonne affinité pour les récepteurs associés aux amines traces (taar), notamment taar1. Les composés peuvent être utilisés pour le traitement de la dépression, des troubles anxieux, du trouble bipolaire, de l'hyperactivité avec déficit de l'attention (adhd), des troubles relatifs au stress, des troubles psychotiques tels que la schizophrénie, des maladies neurologiques telles que la maladie de parkinson, des maladies neurodégénératives telles que la maladie d'alzheimer, de l'épilepsie, de la migraine, de l'hypertension, de l'abus d'alcool ou d'autres drogues et de troubles métaboliques tels que les troubles de l'alimentation, le diabète, les complications diabétiques, l'obésité, la dyslipidémie, les troubles de la consommation d'énergie et de l'assimilation, les troubles et le mauvais fonctionnement de l'homéostasie de la température corporelle, les troubles du sommeil et du rythme circadien, et les troubles cardiovasculaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184360 | 2012-09-14 | ||
| PCT/EP2013/068769 WO2014041007A1 (fr) | 2012-09-14 | 2013-09-11 | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37944A1 true MA37944A1 (fr) | 2016-04-29 |
| MA37944B2 MA37944B2 (fr) | 2017-10-31 |
Family
ID=47044779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37944A MA37944B2 (fr) | 2012-09-14 | 2013-09-11 | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9487501B2 (fr) |
| EP (1) | EP2895477B1 (fr) |
| JP (2) | JP2015531782A (fr) |
| KR (1) | KR101706486B1 (fr) |
| CN (2) | CN107903251A (fr) |
| AR (1) | AR092537A1 (fr) |
| AU (1) | AU2013314388B2 (fr) |
| BR (1) | BR112015004511B1 (fr) |
| CA (1) | CA2882821C (fr) |
| CL (1) | CL2015000580A1 (fr) |
| CR (1) | CR20150087A (fr) |
| DK (1) | DK2895477T3 (fr) |
| EA (1) | EA026062B1 (fr) |
| ES (1) | ES2654653T3 (fr) |
| HK (2) | HK1252981A1 (fr) |
| HR (1) | HRP20171981T1 (fr) |
| HU (1) | HUE037689T2 (fr) |
| IL (1) | IL237332B (fr) |
| LT (1) | LT2895477T (fr) |
| MA (1) | MA37944B2 (fr) |
| MX (1) | MX363362B (fr) |
| MY (1) | MY178667A (fr) |
| NO (1) | NO2895477T3 (fr) |
| NZ (1) | NZ705154A (fr) |
| PE (1) | PE20150735A1 (fr) |
| PH (1) | PH12015500489A1 (fr) |
| PL (1) | PL2895477T3 (fr) |
| PT (1) | PT2895477T (fr) |
| RS (1) | RS56747B1 (fr) |
| SG (1) | SG11201501958QA (fr) |
| SI (1) | SI2895477T1 (fr) |
| TW (1) | TWI610926B (fr) |
| UA (1) | UA113776C2 (fr) |
| WO (1) | WO2014041007A1 (fr) |
| ZA (1) | ZA201501126B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101800594B1 (ko) * | 2014-07-30 | 2017-11-22 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar) 조절제로서 6-아미노-5,6,7,8-테트라하이드로나프탈렌-2-일 또는 3-아미노크로만-7-일 유도체 |
| HUE050986T2 (hu) | 2016-03-17 | 2021-01-28 | Hoffmann La Roche | 5-etil-4-metil-pirazol-3-karboxamid származék, amely TAAR-agonista aktivitású |
| WO2018112420A1 (fr) * | 2016-12-15 | 2018-06-21 | The Regents Of The University Of California | Compositions et procédés pour le traitement du cancer |
| PE20212178A1 (es) | 2019-04-09 | 2021-11-09 | Hoffmann La Roche | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria |
| WO2022262855A1 (fr) * | 2021-06-18 | 2022-12-22 | 上海拓界生物医药科技有限公司 | Inhibiteur de malt1, son procédé de préparation et son utilisation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| TW201236685A (en) * | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
-
2013
- 2013-09-11 AU AU2013314388A patent/AU2013314388B2/en active Active
- 2013-09-11 KR KR1020157009118A patent/KR101706486B1/ko active IP Right Grant
- 2013-09-11 RS RS20171358A patent/RS56747B1/sr unknown
- 2013-09-11 PE PE2015000364A patent/PE20150735A1/es active IP Right Grant
- 2013-09-11 SI SI201330900T patent/SI2895477T1/en unknown
- 2013-09-11 MX MX2015002900A patent/MX363362B/es unknown
- 2013-09-11 NO NO13759754A patent/NO2895477T3/no unknown
- 2013-09-11 UA UAA201503288A patent/UA113776C2/uk unknown
- 2013-09-11 PT PT137597548T patent/PT2895477T/pt unknown
- 2013-09-11 EA EA201590454A patent/EA026062B1/ru not_active IP Right Cessation
- 2013-09-11 CA CA2882821A patent/CA2882821C/fr active Active
- 2013-09-11 CN CN201711272710.XA patent/CN107903251A/zh active Pending
- 2013-09-11 NZ NZ705154A patent/NZ705154A/en unknown
- 2013-09-11 BR BR112015004511-1A patent/BR112015004511B1/pt active IP Right Grant
- 2013-09-11 WO PCT/EP2013/068769 patent/WO2014041007A1/fr active Application Filing
- 2013-09-11 HU HUE13759754A patent/HUE037689T2/hu unknown
- 2013-09-11 EP EP13759754.8A patent/EP2895477B1/fr active Active
- 2013-09-11 CN CN201380047584.1A patent/CN104619700A/zh active Pending
- 2013-09-11 ES ES13759754.8T patent/ES2654653T3/es active Active
- 2013-09-11 MY MYPI2015000641A patent/MY178667A/en unknown
- 2013-09-11 LT LTEP13759754.8T patent/LT2895477T/lt unknown
- 2013-09-11 DK DK13759754.8T patent/DK2895477T3/en active
- 2013-09-11 PL PL13759754T patent/PL2895477T3/pl unknown
- 2013-09-11 SG SG11201501958QA patent/SG11201501958QA/en unknown
- 2013-09-11 MA MA37944A patent/MA37944B2/fr unknown
- 2013-09-11 JP JP2015531543A patent/JP2015531782A/ja active Pending
- 2013-09-12 AR ARP130103258A patent/AR092537A1/es not_active Application Discontinuation
- 2013-09-13 TW TW102133263A patent/TWI610926B/zh active
-
2015
- 2015-02-18 ZA ZA2015/01126A patent/ZA201501126B/en unknown
- 2015-02-19 IL IL237332A patent/IL237332B/en active IP Right Grant
- 2015-02-20 CR CR20150087A patent/CR20150087A/es unknown
- 2015-03-06 PH PH12015500489A patent/PH12015500489A1/en unknown
- 2015-03-09 CL CL2015000580A patent/CL2015000580A1/es unknown
- 2015-03-13 US US14/656,853 patent/US9487501B2/en active Active
- 2015-07-27 HK HK18112341.1A patent/HK1252981A1/zh unknown
- 2015-07-27 HK HK15107153.1A patent/HK1206720A1/xx unknown
-
2017
- 2017-02-22 JP JP2017031116A patent/JP6529998B2/ja active Active
- 2017-12-19 HR HRP20171981TT patent/HRP20171981T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35192B1 (fr) | Derives de pyrazole | |
| MA35194B1 (fr) | Derives de benzamide substitues | |
| EP1363632B1 (fr) | Aminoalkylindoles cannabimimetiques selectifs d'un recepteur | |
| MA32486B1 (fr) | Derives de 4,5- dihydrooxazol-2-yle | |
| MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
| MA37944A1 (fr) | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson | |
| MA33855B1 (fr) | Dérivés de benzamide substitués | |
| MA31165B1 (fr) | Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc | |
| CN85108623A (zh) | 制备具有药用活性的杂环酰胺之新方法 | |
| CN1922149A (zh) | 吡咯和吡唑daao抑制剂 | |
| CN1871240A (zh) | 吡咯并嘧啶酮衍生物 | |
| CN1589269A (zh) | 杂1,2－二氢化茚:一类新型有效的大麻配体 | |
| JP6950534B2 (ja) | テトラヒドロナフタレン誘導体 | |
| MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| MX2012005363A (es) | Derivados de oxazolina para el tratamiento de trastornos del sistema nervioso central (snc). | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
| MX361761B (es) | Derivados de triazol carboxamida. | |
| CN1602292A (zh) | 不饱和的1－氨基－烷基环己烷nmda、5ht3和神经元烟碱性受体拮抗剂 | |
| MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
| MX2009005047A (es) | 4-imidazoles sustituidos. | |
| MX349738B (es) | Derivados de dihidrooxazol-2-amina. |